Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465226 · ClinicalTrials.gov registry record · Phase 4
Oliceridine in Patients With Acute Burn Injuries
A Phase 4 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT05465226: Completed Phase 4 study, sponsored by University of Tennessee.
NCT05465226 is a Phase 4 study that has completed, run by University of Tennessee. The registered enrollment target is 31 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05465226, a Phase 4 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after burn injury. The majority of wound care and dressing changes are completed in non-intubated patients and rates of respiratory depression concerning. Oliceridine is a biased, selective MOR agonist approved for treatment of acute pain. To date there is no literature of use in patients with burn injuries. While it should be effective, efficacy and the potential for reduced adverse events need to be quantified. Current practice and guidelines, plead for better analgesia for patients with burn injuries.
Primary Outcome
Change in Numeric Rating Scale (0 - 10 with 10 being the worst) pain scores after initiation
Interventions
- DRUG Oliceridine
- DRUG Historical opioid use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 4 |
What the finished NCT05465226 record still lists
NCT05465226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Oliceridine is the first listed.
NCT05465226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05465226 about?
NCT05465226 is a clinical study titled "Oliceridine in Patients With Acute Burn Injuries". Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after bu...
What is the current status of trial NCT05465226?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2023-04-01. Estimated completion is 2023-10-24.
What interventions are being tested in trial NCT05465226?
The interventions under investigation include: Oliceridine (DRUG), Historical opioid use (DRUG).
Who is sponsoring clinical trial NCT05465226?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05465226's enrollment target sits among peer trials
31 1544th of 2000 higher than 449 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI